Literature DB >> 12516027

Tuberculosis drug resistance: a global threat.

Jean B Nachega1, Richard E Chaisson.   

Abstract

Resistance to antituberculosis drugs has been a problem since the era of chemotherapy began. After dramatic outbreaks of multidrug-resistant tuberculosis (MDR-TB) in the early 1990s, resistance became recognized as a global problem. MDR-TB now threatens the inhabitants of countries in Europe, Asia, Africa, and the Americas. An understanding of the molecular basis of drug resistance may contribute to the development of new drugs. Management of MDR-TB relies on prompt recognition and treatment with at least 3 drugs to which an isolate is susceptible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12516027     DOI: 10.1086/344657

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

1.  Treatment of chronic infections with rifamycins: is resistance likely to follow?

Authors:  Richard E Chaisson
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

2.  Tetrameric structure of the GlfT2 galactofuranosyltransferase reveals a scaffold for the assembly of mycobacterial Arabinogalactan.

Authors:  Robert W Wheatley; Ruixiang Blake Zheng; Michele R Richards; Todd L Lowary; Kenneth K S Ng
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

3.  A novel mechanism of growth phase-dependent tolerance to isoniazid in mycobacteria.

Authors:  Makoto Niki; Mamiko Niki; Yoshitaka Tateishi; Yuriko Ozeki; Teruo Kirikae; Astrid Lewin; Yusuke Inoue; Makoto Matsumoto; John L Dahl; Hisashi Ogura; Kazuo Kobayashi; Sohkichi Matsumoto
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

4.  In-house phage amplification assay is a sound alternative for detecting rifampin-resistant Mycobacterium tuberculosis in low-resource settings.

Authors:  Norberto Símboli; Howard Takiff; Ruth McNerney; Beatriz López; Anandi Martin; Juan Carlos Palomino; Lucía Barrera; Viviana Ritacco
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.

Authors:  Anandi Martin; Juan Carlos Palomino; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 6.  Whole-genome sequencing in outbreak analysis.

Authors:  Carol A Gilchrist; Stephen D Turner; Margaret F Riley; William A Petri; Erik L Hewlett
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

7.  Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Yu Pang; Hui Xia; Zhiying Zhang; Junchen Li; Yi Dong; Qiang Li; Xichao Ou; Yuanyuan Song; Yufeng Wang; Richard O'Brien; Kai Man Kam; Junying Chi; Shitong Huan; Daniel P Chin; Yanlin Zhao
Journal:  J Clin Microbiol       Date:  2013-03-20       Impact factor: 5.948

8.  Evaluation of a semi-automated reporter phage assay for susceptibility testing of Mycobacterium tuberculosis isolates in South Africa.

Authors:  Niaz Banaiee; Vanessa January; Charmaine Barthus; Maureen Lambrick; Denise Roditi; Marcel A Behr; William R Jacobs; Lafras M Steyn
Journal:  Tuberculosis (Edinb)       Date:  2007-11-05       Impact factor: 3.131

9.  In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.

Authors:  Manoj Kumar; Rajakrishnan Vijayakrishnan; Gita Subba Rao
Journal:  Mol Divers       Date:  2009-08-21       Impact factor: 2.943

10.  Drug resistant strains of Mycobacterium tuberculosis identified through PCR-RFLP from patients of Central Punjab, Pakistan.

Authors:  Muhammad Riaz; Zahed Mahmood; Muhammad Tariq Javed; Irum Javed; Muhammad Shahid; Mazhar Abbas; Syed Ehtisham-Ul-Haque
Journal:  Int J Immunopathol Pharmacol       Date:  2016-04-11       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.